2D and 3D Single Use Bioprocess Bag Market

Key data points: Market size in 2027 = $7.6 billion and 2035 = $25.6 billion growth forecast = 14.3% annually for the next 8 years. This market report covers Trends, opportunities and forecasts in 2D and 3D single use bioprocess bag market to 2035 by type (EVA, ULDPE, and others), application (buffer & culture medium, stock solution storage, intermediate product storage, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) 2D and 3D Single Use Bioprocess Bag Market The future of the global 2d and 3d single use bioprocess bag market looks promising with opportunities in the buffer & culture medium, stock solution storage, and intermediate product storage markets. The global 2d and 3d single use bioprocess bag market is expected to reach an estimated $25.6 billion by 2035 from $7.6 billion in 2027 with a CAGR of 14.3% from 2027 to 2035. The major drivers for this market are the increase in healthcare investments, the rising adoption of disposable bioprocessing technologies, and the growing demand for biopharmaceuticals. • Lucintel forecasts that, within the type category, eva is expected to witness higher growth over the forecast period due to the growing demand for higher-performance materials. • Within the application category, buffer & culture medium is expected to witness the highest growth over the forecast period due to the increasing need for efficient storage. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the rising investments in biotechnology sectors. Emerging Trends in 2D and 3D Single Use Bioprocess Bag Market 2D and 3D Single Use Bioprocess Bag Market is in transition from simple fluid containment toward engineered systems that support the production of intensified biologics. Between 2025 and 2027, manufacturers will be focused on performance, speed, and resilience of the supply chain and flexible formats for cell and gene therapy. Lucintel thinks that facility demands will lead to increased technology differentiation. • Sustainability: Suppliers are focusing on improving bag yield and lifecycle while publishing data on bag sustainability; Sartorius revealed its continued investment on sustainability in its 2025 report and more industry organizations are starting to evaluate single-use plastics. suppliers publish. Customers will start shifting to more sustainable options in the next three to five years as biomanufacturers evaluate the trade-offs between sustainability and cost to the environment. • Automation: Automated bag assembly with integrated, digitally controlled processes for weighing, mixing, sampling, and aseptic connections will be a focus in the 2027 time frame; sensor-ready assemblies and closed processing will be included in 2027 facility projects. Operator interventions will be further reduced with a focus on automation to retain consistent and accurate records with increased processing volumes. • Advanced Materials: Extractables-and-leachable (E&L) testing in combination with improved weld zones and advanced multilayer films will continually increase the applicability of single-use bags; leading suppliers continue to qualify films for storage temperatures from approximately −80°C to ambient conditions in 2025–2027. Material advancements will keep single-use processing safe and prevent a return to more complex systems. • Cell and Gene Therapy Customization: The manufacturing of smaller batches and growing demand for more personalized therapies will drive the need for more specialized bags and tubing; by 2025, thousands of cell and gene therapy clinical trials will be underway worldwide. Flexible low-volume manufacturing systems that require fewer steps and minimize material loss will be essential, and manufacturers will have to adjust their product designs. • Regional Supply Diversification: Drug manufacturers are qualifying secondary suppliers of film, components, and assemblies across North America, Europe, and Asia; during 2025, capacity announcements showed continued investments in local bioprocessing. Diversification will be necessary as shortages, trade challenges, and qualification issues will disrupt scheduled inventory demands. For the next 3 years, the main competing factors for 2D and 3D Single Use Bioprocess Bags will be depth of validation, film performance, resilience of supply, and lifecycle data. The strongest demand will be for biologics, however cell and gene therapies will develop more specific requirements. The winners will combine a standardized offering of platforms with application-specific engineering and provide predesigned rapid changeover systems to satisfy the challenges of multi-jurisdictional and spans regulatory production systems. Recent Developments in the 2D and 3D Single Use Bioprocess Bag Market Activity in the 2d and 3d single use bioprocess bag market is picking up from now up to 2025-2027 as biopharma manufacturers focus on setting up flexible capacity and decreasing cleaning requirements. Lucintel anticipates greater focus on higher volumes of bags, stronger films, improved sensors, and regional supply assurance. The highest levels of interest are focused on the commercialization of biologics, cell and gene therapies, and contract manufacturing. • Capacity Build Out: Sartorius built up its bioprocess manufacturing capacity in 2025 and now meets customer demand for Flex safe bags and related frameworks. (January 2025). Larger regional installations will provide customers shorter lead times to standardize single-use systems across their production sites. • Technology Build Out: Thermon Fisher Scientific introduced new bag assemblies and integrated sensors in 2025 to provide customers with greater process control and reduced changeover times. (March 2025) • Strategic Partnership: Cytiva and a large biopharma customer deepened their partnership on high impact single use systems and integrated fluid management systems in 2025.(June 2025). • Local Production: For 2025, Merck continued to invest in localized flexible single-use manufacturing, focused on supply chain resilience for European and North American customers (September 2025). Local production will help alleviate supply chain disruptions and concerns related to specialized component shortages and export controls. • CDMO Growth: Disposable bioreactors and formulation capacity at CDMO’s was added in 2025, along with new facilities constructed on a 2D and 3D bag platform (November 2025). The growth of CDMO suites is important as it means continuous demand for bags, tubing, connectors, and spare units. In the next 5 years, the industry will increasingly favor suppliers that provide consistent films, extractable data, automation integration, and regional supply consistency at a competitive price. There will be a greater emphasis on the cost of lost production. Suppliers that integrate bag manufacturing, sensors, assemblies, and provide complete service support will win the largest margins as commercial biologics continue to grow. Strategic Growth Opportunities in the 2D and 3D Single Use Bioprocess Bag Market Manufacturers continue to shift bioprocessing designs between 2024 and 2026 to incorporate more flexible capacity. Faster changeovers and lower exposure to contamination will be included. The demand is beyond the standard cell-culture bags, and there is a need for fit-for-purpose formats for the intensified and/or vaccine production or gene therapy bags. Lucintel predicts that the market will grow even more with single-use technology adoption in smaller facilities and in the emerging markets. • Advanced Therapy Applications: Bag suppliers of single-use, 2D or 3D bioprocessing, can modify assemblies designed for use in viral vectors, cell therapies or mRNA workflows. In January 2025, the FDA approved more than 40 cellular and gene therapy products. The demand for closed, disposable, and easy-to-validate systems for the production of small batches will grow. • High-performance Premium Bags: Multilayer films with low extractables and strong seals will have higher margins. In April 2025, Sartorius reported that their single-use products for biopharmaceutical manufacturing reach more than 110 countries. In the next 3 to 5 years, these sensitive processes will drive the industry to buy based on performance rather than price. • Expanding Into Emerging Markets: The establishment of local inventories and technical support can increase adoption of contract manufacturers in India, Southeast Asia, and Latin America. In February 2025, the Indian Department of Pharmaceuticals recognized 10 focus areas under its biopharmaceutical growth initiative. The growth of regional production will create demand for standardized bags and shorten replenishment cycles. • Digital Manufacturing: Disposable plastic bags will become traceable process assets through the use of sensors, serialized components, and electronic batch records. In May 2025, the European Medicines Agency noted that in their reviews of over 25 percent of the advanced therapy applications, complex manufacturing controls were present. Digital traceability will enhance process control, reduce deviations, and improve supplier differentiation during audits. • Circularity and Recovery Services: Plastic recycling and take-back programs, along with lower-material designs, can provide new streams of revenue beyond bag sales. In March 2025, the BioPhorum community grew to include more than 150 member organizations focused on biomanufacturing sustainability. Environmental reporting will likely move customers to choose suppliers that quantify waste and provide credible end-of-life options. Over the next five years, the best margins will accrue to suppliers who integrate advances in film science with application engineering. Growth will not be dictated by bag volume alone. It will be the establishment of central manufacturing with reduced customer qualification time and production support for remote manufacturing, and the extension of service contracts. Companies who localize technical support, improve supply resilience, and document extractable performance will gain long-term market share. 2D and 3D Single Use Bioprocess Bag Market Drivers and Challenges The 2d and 3d single use bioprocess bag market is a combination of the disruptive force of technology, the booming biopharmaceutical sector along with an equally disruptive economy and evolving regulations. As Lucintel indicates, flexibility, sustainability, and supply-chain resilience, along with the control of contamination, affect adoption. While the market is explosive, limitations in materials, lengthy validation, and the disposal of used bags create challenging conditions to both the manufacturers and users of the bags. The factors responsible for driving this market include: • Increase in Demand for Biopharmaceuticals: The increased production of vaccines, monoclonal antibodies, cell therapies, and recombinant proteins has created demand for single use bags. The majority of the large, global, pharmaceutical companies favor flexible, multiproduct facilities capable of smaller batch production. The approval of 50 new drugs by the U.S. Food and Drug Administration (FDA) in 2025 has increased investment in bioprocessing infrastructure. This driving force will remain active in the next 3 to 5 years. The demand for faster deployment of contamination control systems capable of supporting personalized medicines and biologics will continue to drive the market. • Technology Advancements: Developments across multiple technologies, including thin film technologies, high integrity connectors, and sensors along with automation and 3-D bag design, are improving performance and visibility in processes. Advanced bag technologies are able to provide enhanced performance for cell and gene therapy manufacturing and reduce hold-up volumes as well as facilitate better mixing. In 2025, the expected integration of digital bioprocessing platforms with disposable sensors will allow for process monitoring of at least four critical process metrics (temperature, pressure, pH, and dissolved oxygen). Improvements to enable real-time process control, lessen the need for manual intervention, and enhance process consistency and repeatability will facilitate the adoption of single-use technologies for advanced manufacturing in the next 3 to 5 year time frame. • Regulatory & Quality Support: Increased flexibility and risk-based thinking concerning single-use technologies has increased single-use technology adoption among biopharmaceutical manufacturers. Increased cohesion in the ICH (International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use) has increased enforcement of regulatory standards with a greater alignment of quality expectations across regulatory members. This increased regulatory cohesion will drive market growth in the next 3 to 5 year time frame as manufacturing suppliers will be able to adopt more consistent documentation and reduce variability in approval requirements. • Sustainability & Resource Efficiency: Single-use bags require fewer water resources and cleaning chemical use, and require less validation and instrument downtime compared to reusable stainless-steel systems. When considering energy use, smaller required infrastructure supports less energy use during construction and process operation. Currently, single-use processes require significantly less water per process step than reusable systems due to the reduced need for multiple process cleaning. This trend will continue and be important in the next 3 to 5 years as biopharmaceutical companies make environmental goals. They will also measure the use of resources and work towards more efficient, less burdensome manufacturing. • Flexible Manufacturing & Cost Advantages: Disposable bags support quick process changes, minimize risk of cross contamination, and support the production of multiple products in multiple batches with demand production close to the end user. This is beneficial for contract manufacturers, clinical development organizations, and manufacturers producing numerous medical products in demand. In 2025, single-use modular facilities were constructed in < 24 months compared to most multi year traditional construction. Over the next 3 to 5 years, manufacturers will use these modular single-use systems because of the advantage of flexibility with decreased costs for each unit of manufacture and greater product immersion. The challenges facing this market include: • Material and Performance Limitations: Permeability, brittleness, stress cracking, welding defects, and a limited compatibility with harsh chemicals and long process times affect polymer films. Three-dimensional bags must have reliable geometry and minimized flow and mechanical strain. In 2025, a lot of suppliers continued to qualify multilayer films comprising at least three functional layers to balance strength, flexibility and barrier protection. These limitations will have a market impact in the next 3 to 5 years because more demanding processes require improvement in materials, extensive testing, and stronger quality assurance from suppliers. • Extractables, Leachables, and Regulatory Validation: Issues with leaching from bags into process streams can impact product safety and affect approval by the regulatory agencies. Resin composition, the impact of sterilization, exposure time, temperature, and process conditions must be evaluated by manufacturers. In 2025, biopharmaceutical validation programs assessed many potential extractable compounds before approving critical single-use assemblies. This will impact the market over the next 3 to 5 years as there will be increasingly sensitive therapies and stricter expectations of quality leading to increased costs, longer qualification periods, and preference toward suppliers with greater analytical ability and demonstrated transparency. • Supply-Chain, Waste, and Cost Pressure: Reliance on specialized polymers, films, connectors, and sterilization capacity can create supply shortages, long lead times, and unpredictable pricing. Post-use, bags can become solid waste and require controlled disposal or intensive, energy-consuming waste treatment. In 2025, many manufacturers continued qualifying at least two suppliers for critical single-use components in order to reduce disruption exposure. These factors will affect the market within the next 3-5 years and will lead to increased regional manufacturing, larger buffers of inventory, research towards recycling, and better design with improved efficiencies, but may discourage cost-sensitive manufacturers from adopting the technology. Flexible production, digital monitoring, and resource-efficient manufacturing reshape biopharmaceutical demand, which will drive the bioprocess single-use bag market in the 2nd and 3rd generations, respectively. Regulatory frameworks and product innovation will support the use of single-use bioprocess bags in clinical and commercial applications. In respective, suppliers who are able to consistently produce films, documents, and bags with sustainable designs, and flexible production, will be able to secure market share. Market success will ultimately depend on a balance of faster, cleaner, and lower cost manufacturing and fulfilling quality, safety, environmental, and operational requirements. List of 2D and 3D Single Use Bioprocess Bag Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies 2d and 3d single use bioprocess bag market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the 2d and 3d single use bioprocess bag market companies profiled in this report include- • Cytiva • CellBios • Entegris • Saint-Gobain Life Sciences • Sentinel • LePure Biotech • Cobetter • Tofflon • Sartorius • Biolink 2D and 3D Single Use Bioprocess Bag Market by Segment The study includes a forecast for the global 2d and 3d single use bioprocess bag market by type, application, and region. 2D and 3D Single Use Bioprocess Bag Market by Type [Value ($B) from 2019 to 2035]: • EVA • ULDPE • Others 2D and 3D Single Use Bioprocess Bag Market by Application [Value ($B) from 2019 to 2035]: • Buffer & Culture Medium • Stock Solution Storage • Intermediate Product Storage • Others 2D and 3D Single Use Bioprocess Bag Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the 2D and 3D Single Use Bioprocess Bag Market Biomanufacturing localization, supply chain investments, and regulatory support are shaping the 2d and 3d single use bioprocess bag market between 2025 and 2027. During this period, suppliers will increase regional production and qualification. According to Lucintel’s most recent assessment, such actions will be critical to industry positioning. • United States: Domestic biomanufacturing investments continue to grow in the U.S. In April 2025, Resilience was awarded $75 million by the Department of Defense to expand its U.S. based pharmaceutical manufacturing. Cytiva, and other vendors, are continuing to qualify single use systems for Advanced Therapy Medicinal Products (ATMPs). Over the next 3-5 years, investments will enable bag production, decrease the time required to validate, and increase the demand for larger, customized bag assemblies. • China: Industrial policies and capacity additions are driving China to localize bioprocessing supply chains. WuXi Biologics reached 135,000 L bioreactor capacity globally in March 2025, and expanded the manufacturing and development capacity in China. Over the medium term, localization will result in domestic sourcing for 2D bags, 3D bags, films, connectors, and integrated assemblies. • Germany: Sartorius continues to invest significantly in its German manufacturing, achieving €3.4 billion of 2024 revenue in February 2025 and expanding the single use technology, including bags and assemblies. Through 2030, the entire value chain, including equipment, film, and pharmaceutical manufacturing, strengthens European bag qualification, automation, and export capacities. • India: The BioE3 policy (Aug. 2024) offers biomanufacturing support and expands biological production. The Indian government’s Department of Biotechnology allocated ₹2,000 crore for the National Biopharma Mission. The policy driven build-out of biomanufacturing should increase adoption of locally sourced baggage as manufacturing capacity for vaccines, biosimilar and cell therapy increases. • Japan: The Yokohama expansion of AGC Biologics biomanufacturing facilities occurs in coordination with the identification of a 2,000-liter mammalian-cell bioreactor in the company’s Japanese operations in January 2025. Domestic manufacturing of biopharmaceuticals is further supported by the Japanese government’s Ministry of Economy, Trade and Industry. Rising capacity increases the need for validated single-use bags and reduces the need for imported systems. Features of the Global 2D and 3D Single Use Bioprocess Bag Market Market Size Estimates: 2d and 3d single use bioprocess bag market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: 2d and 3d single use bioprocess bag market size by type, application, and region in terms of value ($B). Regional Analysis: 2d and 3d single use bioprocess bag market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the 2d and 3d single use bioprocess bag market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the 2d and 3d single use bioprocess bag market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the 2d and 3d single use bioprocess bag market by type (EVA, ULDPE, and others), application (buffer & culture medium, stock solution storage, intermediate product storage, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?